trial

Efficacy of Galantamine to Treat Schizophrenia

NCTId NCT00232349
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Terminated
Enrollment 21 (actual)
Sponsored by Seattle Institute for Biomedical and Clinical Research
Primary completion 2007-06
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Terminated
Enrollment
21 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Single Group
Masking
None
Start
2005-02
Primary completion
2007-06
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
Galantamine

Sponsors

Seattle Institute for Biomedical and Clinical ResearchLead Sponsor

Investigators

1
Andre Tapp, M.D.Principal Investigator

Sites

1 total
Tacoma, United States

Facts & assertions

4 sourced
Enrollment
21
Phase
PHASE4
Primary Completion Date
2007-06
Status
TERMINATED
relationships
The graph out of here
drug
Galantamine
drug
lead_sponsor
Seattle Institute for Biomedical and Clinical Research
company
indication
Schizophrenia
indication
Schizophrenia
indication
Psychotic Disorder
indication
investigator
Andre Tapp, M.D.
person